Literature DB >> 12514424

CD8+ T cell tolerance and cancer immunotherapy.

Karin E De Visser1, Ton N M Schumacher, Ada M Kruisbeek.   

Abstract

To provide protection against all foreign pathogens one can possibly encounter during their lifetime, the T cell repertoire has to be as diverse as possible. At the same time, it is desirable that the T cell repertoire remains unresponsive towards healthy tissues. To realize this self/nonself discriminatory property, T cells undergo tightly controlled selection processes during maturation in the thymus. The key parameter determining the outcome of these selection processes is the avidity of the T cells for self-MHC/self-peptide complexes expressed in the thymus; low avidity interactions result in positive selection, whereas high avidity interactions lead to negative selection. Despite the selection processes, self-tolerance is far from absolute. In many cases, this is due to the presence of self-antigen in the thymus at a level that is too low to induce thymic deletion. In addition, T cells with a low avidity for ubiquitously expressed self-antigens can escape clonal deletion and enter the periphery. A thorough understanding of the self-specific T cell repertoire is important because many potential targets for cancer immunotherapy are self-proteins. In this review, the authors discuss the impact of self-antigen expression on the CD8+ T cell repertoire. An overview of the fate and functional capacities of self-specific T cells with specificity for tissue-restricted self-antigens and for ubiquitously expressed self-antigens is provided. Furthermore, the authors discuss the influence of negative selection on the antitumor reactivity of the mature T cell repertoire.

Entities:  

Mesh:

Year:  2003        PMID: 12514424     DOI: 10.1097/00002371-200301000-00001

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  19 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

2.  MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Authors:  Matthias Leisegang; Susanne Wilde; Stefani Spranger; Slavoljub Milosevic; Bernhard Frankenberger; Wolfgang Uckert; Dolores J Schendel
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

3.  Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.

Authors:  Chelsea M Black; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2014-01-17       Impact factor: 11.151

4.  Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.

Authors:  Charles B Kemmler; Eric T Clambey; Ross M Kedl; Jill E Slansky
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

5.  Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.

Authors:  Jonathan D Buhrman; Kimberly R Jordan; Lance U'ren; Jonathan Sprague; Charles B Kemmler; Jill E Slansky
Journal:  Cancer Res       Date:  2012-11-16       Impact factor: 12.701

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

8.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 9.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

10.  Liver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+CD11b+ myeloid cells.

Authors:  Mitchell Thorn; Gary R Point; Rachel A Burga; Cang T Nguyen; N Joseph Espat; Steven C Katz
Journal:  J Leukoc Biol       Date:  2014-08-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.